Technology Acquisition and independent R&D
Fosun Kite’s investigational product FKC876 (US trade name Yescarta) has obtained the IND approval from NMPA for registrational clinical trials in China. It will be developed for the treatment of relapsed or refractory large B-cell lymphoma after line 2 or more systemic treatment, including diffuse large B-cell lymphoma (DLBCL) of non-specific type, primary mediastinal B-cell lymphoma (PMBCL), B-cell lymphoma of high-grade and DLBCL transformed from follicular lymphoma.
Yescarta is the world's first approved CAR-T cell therapy for adult patients with certain types of non-Hodgkin lymphoma (NHL). FDA approved Yescarca for the US market in October, 2017, followed by EMA for EU markets in August, 2018. According to the ZUMA-1 clinical results released by Kite Pharma, among 101 patients with refractory large B-cell lymphoma, at two years after being treated with Yescarta, the best objective response showed an overall response rate of 83%, with 58% of patients having achieved a complete response. At a median of 15.1 months post-infusion, 42% of patients remained in response, including 40% in complete remission. At a median of 27.1 months post-infusion, 39% of patients remained in response, including 37% in complete remission.
Meantime, by building independent R&D capability, Fosun Kite is committed to developing more innovative immunotherapy products to enrich the company's pipeline and open up for more therapeutic areas.